Benjamin J. Samelson-Jones

Hematology | Oncology

3401 Civic Center Blvd
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Cardiotoxic Effects and Microdystrophin Expression after Gene Therapy for DMD.

Cardiotoxic Effects and Microdystrophin Expression after Gene Therapy for DMD.

Journal: The New England journal of medicine

Published: July 22, 2026

Of Mice and FVIIIa-Mimetics: New Hemophilia A Models for In Vivo Evaluation.

Of Mice and FVIIIa-Mimetics: New Hemophilia A Models for In Vivo Evaluation.

Journal: Blood advances

Published: June 23, 2026

Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with FIX-Fc or N9-GP extended half-life FIX concentrates.

Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with FIX-Fc or N9-GP extended half-life FIX concentrates.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 26, 2026

Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery.

Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery.

Journal: The New England journal of medicine

Published: May 13, 2026

Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management.

Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management.

Journal: Human gene therapy

Published: February 13, 2026

Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B.

Safety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B.

Journal: Blood advances

Published: November 21, 2025

Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B.

Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B.

Journal: Blood advances

Published: November 21, 2025

Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns.

Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: May 12, 2025

Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.

Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.

Journal: The New England journal of medicine

Published: April 16, 2025

"An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B": comment from Lee et al.

"An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B": comment from Lee et al.

Journal: Journal of thrombosis and haemostasis : JTH

Published: March 20, 2025

Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis.

Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis.

Journal: bioRxiv : the preprint server for biology

Published: February 03, 2025

Ex vivo lentiviral gene therapy for severe hemophilia A: an alternative to recombinant adeno-associated viral-based strategies?

Ex vivo lentiviral gene therapy for severe hemophilia A: an alternative to recombinant adeno-associated viral-based strategies?

Journal: Research and practice in thrombosis and haemostasis

Published: January 23, 2025

Showing 1-12 of 56

Last Updated: 09/26/2026